InvestorsHub on MSN

Lilly reports strong phase 3 results for Retevmo in early-stage lung cancer (LLY)

Eli Lilly and Company (NYSE:LLY) announced positive data from its Phase 3 LIBRETTO-432 trial, showing that Retevmo significantly lowered the risk of disease recurrence or death in patients with ...

Revolution Medicines reports phase 3 win in pancreatic cancer

Revolution Medicines (RVMD) reported Phase 3 clinical trial results showing its experimental cancer drug daraxonrasib ...

CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide

With a 5-year dividend growth rate of 15.23%, Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years. In a CNBC report published on May 21, ...
The Manila Times

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that ...
Morningstar

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the ...
Medical Dialogues

Mount Sinai dermatologist reports Phase 3 success for rocatinlimab in moderate-to-severe eczema

Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the ...
Seeking Alpha

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...